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ABSTRACT
Trisomy 21 (T21), Down Syndrome (DS) is the most common genetic cause of dementia and
intellectual disability. Modeling DS is beginning to yield pharmaceutical therapeutic interven-
tions for amelioration of intellectual disability, which are currently being tested in clinical trials.
DS is also a unique genetic system for investigation of pathological and protective mechanisms
for accelerated ageing, neurodegeneration, dementia, cancer, and other important common dis-
eases. New drugs could be identiﬁed and disease mechanisms better understood by establish-
ment of well-controlled cell model systems. We have developed a ﬁrst nonintegration-
reprogrammed isogenic human induced pluripotent stem cell (iPSC) model of DS by reprogram-
ming the skin ﬁbroblasts from an adult individual with constitutional mosaicism for DS and sep-
arately cloning multiple isogenic T21 and euploid (D21) iPSC lines. Our model shows a very low
number of reprogramming rearrangements as assessed by a high-resolution whole genome
CGH-array hybridization, and it reproduces several cellular pathologies seen in primary human
DS cells, as assessed by automated high-content microscopic analysis. Early differentiation
shows an imbalance of the lineage-speciﬁc stem/progenitor cell compartments: T21 causes
slower proliferation of neural and faster expansion of hematopoietic lineage. T21 iPSC-derived
neurons show increased production of amyloid peptide-containing material, a decrease in mito-
chondrial membrane potential, and an increased number and abnormal appearance of mito-
chondria. Finally, T21-derived neurons show signiﬁcantly higher number of DNA double-strand
breaks than isogenic D21 controls. Our fully isogenic system therefore opens possibilities for
modeling mechanisms of developmental, accelerated ageing, and neurodegenerative pathologies
caused by T21. STEM CELLS 2015;33:2077–2084
INTRODUCTION
Trisomy 21 (T21), Down Syndrome (DS) is the
most common genetic cause of intellectual dis-
ability and dementia with rising global preva-
lence [1]. Several phenotypes have been
observed at molecular and cellular levels that
reproduce in primary tissues from human indi-
viduals with T21. Some of these cellular pheno-
types directly map onto clinical components of
DS; these include intellectual disability, defects
in cognitive development and age-related cogni-
tive decline, Alzheimer’s disease-like dementia,
epilepsy, congenital heart defect, childhood leu-
kemia, and others [2–12]. Modeling DS is begin-
ning to yield pharmaceutical therapeutic
interventions for amelioration of intellectual
disability which are currently being tested in
clinical trials. New drugs could be identiﬁed by
high throughput screening of chemical libraries
using cellular assays, and therefore well-
controlled cellular model systems are required.
In order to eliminate effects of wide phenotypic
differences among individuals with DS, the
requirement for many experimental purposes
has become the use of an isogenic induced plu-
ripotent stem cell (iPSC) model for DS, where
the sole difference between iPSC lines is the
presence of the third chromosome 21.
Several recent iPSC models of DS have been
developed. All of these (with one exception)
used integrational reprogramming. All of these
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reprogrammed cells were derived from fetal, neonatal, or 1
year old infant DS; actually, three studies [13–15] used the
same iPSC lines as a starting point [16]. Some of these studies
report defects in neural progenitor cell (NPC) proliferation [17],
neurogenesis [13], gliogenesis, and neurite outgrowth [18],
others defects in synaptic morphology and function, mitochon-
drial dysfunction [19], and increased amyloid deposition [15].
Other models show increased propensity to generate hemato-
poietic precursors and increased multilineage myeloid hemato-
poiesis potential [14, 20]. Most of these results have been
generated on nonisogenic comparisons, with isogenic lines
either serendipitously generated in cell culture [14, 19] or using
an ingenious but with complex and laborious approach to
silence the third chromosome 21 [13, 21]. In some cases, noni-
sogenic lines were pooled with one isogenic line [14, 19]. In
one study, a unique case of heterokaryotypic twin fetal cells
was exploited [17]. None of these papers reported a genome-
wide high-resolution array-comparative genomic hybridization
(aCGH) analysis of the resulting iPSCs for the rigorous measure-
ment of the artiﬁcial copy-number rearrangements known to
frequently occur during the reprogramming process.
Here we present the ﬁrst iPSC DS model which is both
nonintegrationally reprogrammed and fully isogenic and the
ﬁrst derived from an adult individual with DS which is a con-
stitutional mosaic. Furthermore, we verify the high level of
genome integrity of the resulting iPSCs by showing a very low
number of reprogramming rearrangements as assessed by a
high-resolution whole genome aCGH, and we make entirely
isogenic comparisons of three trisomic and three disomic iPSC
lines derived from this model. This approach minimizes the
inﬂuence of any copy number ﬂuctuations additional to T21
and eliminates genotypic difference noise, allowing the
“clean” detection of T21-causing effects. Our model reprodu-
ces several T21 cellular pathologies seen in primary human
DS cells but hitherto not reported in iPSC models, such as
abnormalities in mitochondrial number and size and an
increase in DNA double-strand breaks in neurons.
MATERIALS AND METHODS
Detailed methods are shown in Supporting Information online.
RESULTS
We generated the iPSCs by nonintegration reprogramming
using temperature-sensitive Sendai virus [22] from primary skin
ﬁbroblasts from a young adult diagnosed with constitutional
mosaicism for DS (strategy illustrated in Supporting Information
Fig. S1). We isolated individual clones (labeled as C[number]),
expanded them, and conﬁrmed that they tested positive for
alkaline-phosphatase expression, and the presence of markers
of pluripotency (Fig. 1A). The Sendai virus was efﬁciently
removed after 7–10 passages (Fig. 1B). Demethylation of the
endogenous NANOG promoter in the iPSCs, compared to the
parental skin ﬁbroblasts, was established via bisulﬁte sequenc-
ing (Fig. 1C). Individual clones were analyzed by rigorous
whole-genome microsatellite DNA ﬁngerprinting, which estab-
lished the presence of clones with T21, and euploid genome
(D21), which are otherwise isogenic (Fig. 1D). In a preliminary
RNA-seq experiment, the isogenic iPSCs show an expected
increase in transcript levels for the majority of HSA21 genes
(not shown). The genome integrity of the resulting iPSCs is of a
high level, as was assessed by high-resolution, whole genome
aCGH (Supporting Information Fig. S2). The supernumerary
HSA21 is intact and complete in both analyzed trisomic lines
(T21C5 and T21C6), and T21 is stable for at least 17–19 pas-
sages, which is as far as we tested for the presence of T21 (Sup-
porting Information Fig. S2A). After ﬁltering out the copy
number variations (CNVs) that occur commonly in healthy indi-
viduals (using comparison to the Database of Genomic Varia-
tion) we made an in silico comparison with the published
survey of genome-rearrangement artefacts in iPSC generated
by conventional integration-reprogramming [23]. Selecting only
events at the same aCGH resolution and the same passage
number as in our study, we detected a signiﬁcantly lower num-
ber of uncommon CNVs, affecting a signiﬁcantly lower number
of genes in our lines, relative to those generated by classic inte-
grational reprogramming methods (Supporting Information Fig.
S2B, S2C). In compliance with international guidelines for iPSC
nomenclature [24] we name these iPSCs: NIZEDSM1iD21-C3, -
C7, and -C9 for the disomic lines, respectively, and
NIZEDSM1iT21-C5, -C6, -C13 for the trisomic lines, respectively
(henceforward abbreviated to D21C3, D21C7, D21C9, T21C5,
T21C6, and T21C13). Microsatellite DNA ﬁngerprinting was
repeated at later passages and conﬁrmed that trisomy 21 is
retained through routine passaging (Supporting Information
Fig. S2D). The isogenic DS iPSC clones can differentiate into cell
lineages of all three embryonic layers both in vitro and in vivo
(Supporting Information Fig. S3).
After 45 days in culture, using neuronal differentiation via
neuro embryoid body (NEB) protocol (Supporting Information
Methods), both disomic and trisomic neuronal differentiation
cultures were able to produce mature looking neurons express-
ing bIII-tubulin, the inhibitory neurotransmitter GABA, as well
as presynaptic and postsynaptic markers of excitatory synapses,
PSD95 and VGlut (Supporting Information Fig. S4A, S4B, respec-
tively). In order to accelerate neuronal differentiation and
improve yields, we applied a directed neuronal differentiation
protocol using dual SMAD inhibition (Noggin and SB431542),
combined with stimulation of retinoid signaling and the addi-
tion of the Sonic Hedgehog agonist purmorphamine [25]. Both
trisomic and disomic lines were able to produce electrophysio-
logically active neurons (Supporting Information Fig. S4C) that
supported spontaneous action potential ﬁring and functional
whole-cell current responses to saturating concentrations of
externally applied GABA and glycine, observed in neurons from
both D21C3 (at 28 days) and T21C5 lines (at 40 days). In order
to gain an approximate estimate of the proportion of neurons
likely to ﬁre spontaneous action potentials, we used Ca21 imag-
ing and observed multiple Ca21 transients, which would be
indicative of regenerative spontaneous activity in accord with
the ﬁring of spontaneous action potentials (Supporting Informa-
tion Fig. S5A, S5B). Quantiﬁcation of the numbers of neurons
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Figure 1. Isogenic iPSC model of Down Syndrome generated by reprogramming primary human skin ﬁbroblasts from an adult individ-
ual with mosaic Down Syndrome, using a temperature-sensitive Sendai virus. (A): Images of undifferentiated iPSC colonies from two
clones (D21C3, T21C5) after three passages; bright-ﬁeld microphotographs and alkaline phosphatase expression. Further images after
immunohistochemistry for pluripotency markers (SSEA4, TRA 1–60, and TRA 1–81). (B): Spontaneous elimination of the temperature sen-
sitive, nonintegrating Sendai virus (Ts-SeV) from iPSC cells through routine passaging. Primary human skin ﬁbroblasts were infected with
the Ts-SeV for positive control and were stained with an antibody against the SeV protein HN-IL4.1 alongside the iPSC colonies at the
indicated passage numbers (P[n]). The agarose gel shows ampliﬁcation products after reverse transcriptase polymerase chain reaction
(PCR), using SeV (and GAPDH) speciﬁc primers (1) D21C3 P5, (2) T21C5 P7, (3) T21C5 P10, (4) D21C3 P10, (5) untransfected ﬁbroblasts,
(6) SeV infected ﬁbroblasts P0, (7) SeV infected ﬁbroblasts P0—reverse transcriptase, (8) H2O C: Demethylation of endogenous NANOG
promoter following reprogramming: bisulﬁte sequencing analysis of eight CpG dinucleotides in the promoter region of NANOG using
genomic DNA isolated from iPSC D21C3 and T21C5, compared to genomic DNA isolated from the primary mosaic DS skin ﬁbroblasts
that were used for reprogramming. (D): (Left hand panels): Graphs showing semiquantitative microsatellite PCR analysis for two chromo-
some 21 (HSA21) markers and for markers from two euploid chromosomes (HSA5, 18) using genomic DNA isolated from iPSC clones.
Clones T21C5 and T21C6 are trisomic and Clone D21C3 disomic for HSA21. (Right hand panels): Whole genome microsatellite ﬁngerprint
of genomic DNA isolated from iPSC clones, demonstrating that they are isogenic. Abbreviations: Alk Phos, alkaline phosphatase; hiPS
clone, human induced pluripotent stem clone; SeV, Sendai Virus.
Murray, Letourneau, Canzonetta et al. 2079
www.StemCells.com VC 2015 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
exhibiting calcium transients over the 1 minute time course
showed no signiﬁcant difference between D21 and T21 neurons
(Supporting Information Fig. S5B). In addition, under voltage-
clamp conditions, we identiﬁed neuronal sensitivities to GABA
and glycine which indicates the cell surface expression of func-
tional GABAA and glycine receptors. This was apparent in most
cells tested, with no difference noted between T21 and D21
cells (not shown).
To examine early stages of iPSC differentiation an EB pro-
tocol was adopted for both hematopoietic and neuronal dif-
ferentiation, modifying the published method [26]. For
hematopoietic EBs (HEBs) 3,000 live cells in single cell suspen-
sion were allowed to aggregate in a 96-well. Imaging and
analysis of HEBs after 5 days showed that T21 HEBs were sig-
niﬁcantly larger than the euploid controls (Supporting Infor-
mation Fig. S6A). This increase in HEB size was caused by an
Figure 2. Trisomy 21 causes an increase in b-amyloid containing material in and around neurons generated from iPSCs. (A): Neurons
were generated from iPSCs over a 60-day differentiation protocol. Cells were then ﬁxed and stained with an anti-amyloid peptide anti-
body (6E10), which is reactive to amino acids 1–16 in b-amyloid but detects all APP polypeptide forms that contain the epitope. Nuclei
were labeled with Hoechst. Scale bar5 100 lm. (B): Quantiﬁcation of the integrated intensity for the 6E10 stain shows an increase of
APP expression in T21 neurons compared to the isogenic D21 neurons. Image capture and quantiﬁcation were performed using auto-
mated multiparametric analysis on the ImageXpress Micro XL (Molecular Devices) wide-ﬁeld high content imaging system, and data
were analyzed using MetaMorph software. Three wells per cell line and a minimum of 6,000 cells per well were analyzed. Student’s t
test, error bars SEM. Visually, T21 neurons appear to also show more 6E10-reactive aggregates (not quantitated). Zoomed-in images for
T21C6 and D21C7 are shown at the same size and magniﬁcation.
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increase in the cell numbers (Supporting Information Fig.
S6B), which at this stage is predicted to be early hematopoi-
etic mesoderm precursors. A similar result was obtained with
early T21 mesodermal colonies derived from transchromoso-
mic mouse embryonic stem cells [7]. Although the T21 HEBs
gave a higher proportion of CD341 cells (hematopoietic
stem/progenitor lineages) on both days 12 and 18 of further
differentiation (not shown), there was no statistically signiﬁ-
cant difference. By contrast, NPCs derived from NEBs showed
a reduction in proliferation rate. The cumulative population
doublings of trisomic cells was signiﬁcantly reduced during
the expansion of NPCs (Supporting Information Fig. S6C).
Increased cell death is unlikely to be the cause of the
observed decrease population cell doubling, because the pro-
portion of nonviable cells in the same counts shows no
increase in T21 NPCs (Supporting Information Fig. S6D).
Figure 3. Trisomy 21 results in an increase in size and number of mitochondria in neurons generated from induced pluripotent stem
cells (iPSCs). (A): Neurons were generated from iPSCs over a 60-day differentiation protocol. Live cells were then loaded with JC-10 to
assess mitochondrial membrane potential. Healthy mitochondria are labeled in red, while green cytoplasmic staining indicates that JC-10
is diffusing out of the mitochondria due to decreased mitochondrial membrane potential. Representative images for each cell line are
shown. Image capture and quantiﬁcation were performed using automated multiparametric analysis on the ImageXpress Micro XL
(Molecular Devices) wide-ﬁeld high content imaging system, and data were analyzed using MetaMorph software. A total of four wells
and a minimum of 1,500 cells per cell line were imaged and analyzed. Scale bar5 100 lm (identical scale for all images). (B): Quantiﬁ-
cation of the number of mitochondria per cell, and (C) the mean mitochondrial area show that both are increased in T21 neurons com-
pared to the isogenic D21 neurons. (D): Quantiﬁcation of the integrated intensity for the green signal generated by JC-10 shows
decreased mitochondrial membrane potential in T21 neurons compared to the isogenic D21 neurons. Student’s t test, error bars SEM.
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iPSC-derived neurons were analyzed after 60 days of dif-
ferentiation following the dual SMAD inhibition protocol
(mentioned previously, but here minus purmorphamine) that
generates multiple classes of projection neurons from differ-
ent cortical layers [25]. We observed the typical morphology
of neurogenic cortical rosettes as published [27] and con-
ﬁrmed that after 60 days neuronal differentiation, >95% of
cells were Tuj11 (not shown). As this protocol generated
100% excitatory glutamatergic neurons [25, 27], and as no dif-
ferences in the composition of cortical layer subpopulations
were observed between DS and normal human iPSCs [15], we
think it is unlikely that difference in cell type proﬁles would
be responsible for the differences between T21 and D21
observed in our results, although we cannot fully rule out this
possibility. Immunostaining of ﬁxed neurons with an antibody
(6E10) raised against the epitopes in the Ab-peptide, but reac-
tive to all proteolytic fragments of the amyloid precursor pro-
tein that contain this epitope, revealed an increase in total
amyloid staining in trisomic neurons compared to isogenic
euploid controls (Fig. 2A, 2B). This demonstrates that
Figure 4. Trisomy 21 causes an increase in DNA damage in neurons generated from induced pluripotent stem cells (iPSCs). (A): Neu-
rons were generated from iPSCs over a 60-day differentiation protocol. Cells were then ﬁxed and stained with a cH2AX antibody to
detect DNA double-strand breaks. Nuclei were labeled with Hoechst. Scale bar5 100 lm. Enlarged insets for D21C3 and T21C5 double
stained with Hoechst and cH2AX antibody are shown as examples below main images. (B): The number of cH2AX puncta per cell is sig-
niﬁcantly increased in T21 neurons compared to the isogenic D21 neurons. Image capture and quantiﬁcation were performed using
automated multiparametric analysis on the ImageXpress Micro XL (Molecular Devices) wide-ﬁeld high content imaging system, and data
were analyzed using MetaMorph software. Three wells per cell line and a minimum of 6,000 cells per well were analyzed. Student’s t
test, error bars SEM.
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increased amyloid production can be successfully modeled in
these cells. Trisomic neurons also appear to show an increase
in size and number of 6E10-reactive discreet punctiform
aggregates (not quantiﬁed, Fig. 2B zoom). Our staining does
not permit us to conclude if these aggregates are intracellular
or extracellular.
To assess mitochondrial membrane potential in neurons,
live cells were labeled with JC-10 (Fig. 3A). In healthy cells JC-
10 selectively accumulates in the mitochondria and forms
aggregates with a characteristic ﬂuorescent emission at
590 nm (orange/red). If mitochondrial membrane potential is
decreased (due to damaged/unhealthy cells) JC-10 monomers
are formed, which are released into the cytoplasm, resulting
in a shift to green emission at 525 nm. An increase in both
the size and number of mitochondria were observed in the
trisomic neurons (Fig. 3B, 3C), consistent with a previous
study in primary T21 neurons which showed “generalized
perturbations” in T21 mitochondrial structure and function,
including a more fragmented mitochondrial network [9]. Triso-
mic neurons also showed a decreased mitochondrial mem-
brane potential, as evidenced by the increase in green
cytoplasmic staining with JC-10 (Fig. 3D).
Having shown that T21 neurons have a deﬁcit in mito-
chondrial function similar to primary human T21 neurons in
vitro, we anticipate that reactive oxygen species (ROS) pro-
duction is increased in T21 neurons. Increased ROS leads to
increased DNA damage, as measured by the proportion of
cH2AX foci, an in vitro marker of ageing, shown increased in
primary ﬁbroblasts from old, compared to young humans
[28], and in primary neurons from old, compared to young
mice [29]. We assessed the number of cH2AX foci (Fig. 4A).
Fully automated quantiﬁcation of approximately 18,000 cells
per cell line showed a signiﬁcantly increased number of
cH2AX puncta per cell in T21 neurons (Fig. 4B).
DISCUSSION
In conclusion, we report a ﬁrst nonintegration-reprogrammed
isogenic and high genomic ﬁdelity iPSC model from an adult with
mosaic DS. The model reproduces several differentiation, ageing,
and neurodegeneration-related cellular phenotypes associated
with DS pathology and attributable solely to T21 as a cause.
Particularly intriguing are two observations (Figs. 3, 4)
that open a whole set of new interesting mechanistic ques-
tions. Increased number of mitochondria in neurons could be
related to increased mitochondrial fragmentation observed in
primary DS cortical neurons in culture [9]. On the other hand,
it is possible that T21 mitochondria in DS neurons, which are
high consumers of energy exclusively derived from oxidative
metabolism, are hypofunctional (as has been observed in pri-
mary DS cortical neurons in culture [9]), and the demand for
more energy increases mitochondrial biogenesis. These
hypotheses remain to be tested. Increased number of DNA
double-strand breaks in T21 neurons (Fig. 4) could be further
exploited as a cellular marker of accelerated ageing observed
in DS [10, 30]. Alternatively, more genomic instability in the
nuclei of postmitotic T21 neurons (such as transposition
events) [31] could also explain this observation.
Currently, several interdisciplinary consortia have been
organized to study DS genetics and cellular models integrated
with the assessment of the adult population with DS for neu-
rocognitive function, age-related decline, presence or absence
of dementia and other comorbidities (e.g., see http://www.
ucl.ac.uk/london-down-syndrome-consortium, http://www.psy-
chiatry.cam.ac.uk/ciddrg/research/dementia-in-downs-syn-
drome-dids/). It is therefore important to verify that cellular
phenotypes under-pinning DS pathology can also be repro-
duced in iPSCs derived from an adult individual with DS, as
this had not been reported so far.
Up to 75% of constitutionally T21 concepti spontaneously
die in utero [10, 32] suggesting that in random allelic variation,
the presence of a third copy of HSA21 has a 75% probability to
cause severe phenotypes that are normally missed. In constitu-
tional mosaicism, T21 with an otherwise deleterious genotype
could be rescued by a signiﬁcant (>50%) presence of normal
(D21) cells, which results in varying intensity of clinical DS
defects, often not correlating with the percentage of trisomic
cells in tissues. This presents with a theoretical (but so far never
explored) rationale for T21/D21 cells derived from a constitu-
tionally mosaic DS individual to show more contrasting differen-
ces in cellular phenotypes, than comparisons between cells of
liveborn 100% trisomic individuals. Such phenotypes are more
likely to be robust, reproducible, and therefore more amenable
to developing into high throughput screening assays.
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